Horizon Pharma (HZNP) PT Raised to $35 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
August 7, 2019 7:00 AM EDT
-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent;
Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million --
-- Quarterly Orphan and Rheumatology Segment Net Sales Increased 11 Percent to $223.5 Million;
KRYSTEXXA® Second-Quarter 2019 Net Sales Growth of 36 Percent --
-- Increasing Full-Year 2019 Net Sales Guidance Range to $1.28 Billion to $1.30 Billion and
Adjusted EBITDA Guidance Range to $460 Million to $475 Million;
KRYSTEXXA Full-Year 2019 Net Sales Growth Expected to Be Greater Than 20 Percent --
-- Submitted Teprotumumab U.S. Biologics License Application... More
